Immunocore Holdings plc Adjustments For Finance Income Cost
Immunocore Holdings plc (IMCR) reported Adjustments For Finance Income Cost of GBP 2.77 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceIncomeCost · last filed 2023-08-10
- Immunocore Holdings plc adjustments for finance income cost for the quarter ending 2022-12-31 was -748.00K GBP.
- Immunocore Holdings plc adjustments for finance income cost for the quarter ending 2022-09-30 was -1.19M GBP.
- Immunocore Holdings plc adjustments for finance income cost for the quarter ending 2021-12-31 was -1.34M GBP.
| Period end | Adjustments For Finance Income Cost 3 month | Adjustments For Finance Income Cost 6 month | Adjustments For Finance Income Cost 9 month | Adjustments For Finance Income Cost 12 month | Adjustments For Finance Income Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | 2.77M GBP 6-K · filed 2023-08-10 | ||||
| 2022-12-31 | -748.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -1.94M GBP derived: sum of 2 quarters · filed 2023-03-01 | -4.54M GBP 20-F · filed 2023-03-01 | ||
| 2022-09-30 | -1.19M GBP derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-18 | -3.79M GBP 6-K/A · filed 2022-11-18 | |||
| 2022-06-30 | -2.60M GBP 6-K · filed 2023-08-10 | ||||
| 2021-12-31 | -1.34M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -5.77M GBP 20-F · filed 2023-03-01 | |||
| 2021-09-30 | -4.42M GBP 6-K/A · filed 2022-11-18 | ||||
| 2020-12-31 | -1.17M GBP 20-F · filed 2023-03-01 | ||||
| 2019-12-31 | -7.87M GBP 20-F · filed 2022-03-03 | -7.87M GBP 20-F · filed 2021-03-25 | |||
| 2018-12-31 | 298.00K GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |